Anti-inflammatory antipruritic therapy improves quality of life

Which mediators are causally involved in peripheral and central itch sensitization in the context of prurigo and prurigo nodularis (PN) and contribute to the maintenance of pruritus is currently being analysed in numerous research projects. With dupilumab and nemolizumab, two therapeutic approaches are now available that combine anti-inflammatory and antipruritic effects and have overcome the approval hurdles for the indication PN. Interesting data from pooled analyses and from the long-term extension phase of the respective approval-relevant studies are now available.